Vietnam Biopharmaceutical Market Overview
Base Year: 2024
Historical Years: 2019-2024
Forecast Years: 2025-2033
Market Size in 2024: USD 1.30 Billion
Market Forecast in 2033: USD 2.64 Billion
Market Growth Rate (2025-33): 8.13%
The Vietnam biopharmaceutical market size was valued at USD 1.30 Billion in 2024. Looking forward, the market is expected to reach USD 2.64 Billion by 2033, exhibiting a CAGR of 8.13% during 2025-2033. Southern Vietnam currently dominates the market, holding a significant market share of 40.8% in 2024. The rising chronic disease rates, government healthcare initiatives, burgeoning population, and growing middle-class population base with increased purchasing power. Strategic geographic positioning, collaborations between domestic and international firms, improved regulatory environment, and rising consumer awareness regarding biopharmaceuticals are some of the other factors fueling the Vietnam biopharmaceutical market share.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/vietnam-biopharmaceutical-market/requestsample
Vietnam Biopharmaceutical Market Industry Segmentation:
Vietnam’s biopharmaceutical sector is undergoing a transformative shift, fueled by government support and strong foreign investment. At the heart of this momentum is Resolution 98/NQ-CP, a bold policy that gives Ho Chi Minh City special privileges to attract high-tech industries, including biotech. These reforms are already translating into action—global players like Samsung Biologics are committing over $220 million to establish advanced facilities, while domestic firms such as Traphaco, Vabiotech, and Nanogen are moving up the value chain from basic drug production to more sophisticated biologics and vaccine development. This marks a major step toward reducing the country’s heavy dependence on imported biopharmaceuticals, which currently covers nearly 90% of domestic needs. The broader strategy is not just about self-sufficiency—it’s also about turning Vietnam into a key player in Southeast Asia’s biomanufacturing landscape. There’s growing attention on cutting-edge technologies like monoclonal antibodies and mRNA, with multiple partnerships forming between Vietnamese firms and global leaders to build capacity. These efforts are further supported by workforce training programs and infrastructure investments, which are critical for ensuring long-term sustainability and affordability of biologics targeting diseases that disproportionately affect the region, such as hepatitis and dengue.
Equally important to this transformation is Vietnam’s overhaul of its regulatory environment for biologics. The Drug Administration of Vietnam is pushing for modernization by aligning more closely with international standards, particularly through ASEAN-wide harmonization efforts and reliance pathways based on approvals from the FDA, EMA, and PMDA. These changes are making it faster and more predictable to bring both innovative biologics and biosimilars to market. Recent regulatory updates now offer clearer guidance on biosimilar substitution and post-market surveillance, which builds trust among prescribers and patients alike. Health technology assessment (HTA) processes are also gaining traction, helping authorities evaluate new therapies using real-world data and economic value—key factors for inclusion in Vietnam’s social health insurance programs. Budget constraints remain a challenge, but there are promising signs in the form of pilot reimbursement models and increasing state health expenditure. This regulatory evolution is creating a more favorable environment for international companies, while encouraging domestic players to pursue competitive biosimilar development. Ultimately, this means faster, broader access to treatments for a range of conditions—from cancer and autoimmune diseases to rare disorders.
What’s driving the long-term need for biopharmaceuticals in Vietnam is a marked rise in non-communicable diseases (NCDs). These now account for over three-quarters of all deaths, with cancer, cardiovascular disease, diabetes, and autoimmune disorders becoming alarmingly common. For example, Vietnam now sees more than 180,000 new cancer cases each year—a number that continues to grow. This rise is spurring demand for targeted biologics and immunotherapies, particularly as the healthcare system improves diagnostic capabilities. Biomarker testing and genetic screening are becoming more available, making it possible to tailor therapies more effectively—for example, identifying HER2-positive breast cancer patients who would benefit from trastuzumab. At the same time, rising incomes, a growing middle class, broader insurance coverage, and significant investment in hospital infrastructure are improving both access to and willingness to pay for high-end therapies. Government efforts to prioritize chronic disease management are also playing a role, as is a more informed patient population actively seeking out better treatment options. The intersection of changing disease patterns, better diagnostics, and stronger healthcare infrastructure points to a sustained, long-term rise in demand for advanced biologic drugs across a wide range of conditions.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Vietnam Biopharmaceutical Market Segmentation:
Analysis by Indication:
- Autoimmune Diseases
- Oncology
- Metabolic Disorders
- Others
Analysis by Class:
- Recombinant Proteins
- Monoclonal Antibodies
- Purified Proteins
Regional Analysis:
- Northern Vietnam
- Central Vietnam
- Southern Vietnam
Ask Our Expert & Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=19789&flag=C
- Market Performance (2019-2024)
- Market Outlook (2025-2033)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
